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Abstract
Assessing and improving informed consent understanding is equally important as obtaining
consent from participants in clinical trial research, but developing interventions to target gaps in
participants’ informed consent understanding remains a challenge. We used a randomized
controlled study design to pilot test an educational intervention to improve actual informed
consent understanding of new enrollees in the Adult AIDS Clinical Trial Group (AACTG).
Questionnaires were administered to 24 enrollees to assess their baseline understanding on eight
elements of informed consent associated with AIDS clinical trials. Enrollees who scored
18/21(85%) or less were randomly assigned to in-person, targeted education (intervention) or
delayed education (control). Two follow-up assessments were administered. Repeated measures
ANOVA was performed to determine intervention effectiveness in improving actual informed
consent understanding over time. Actual understanding improved at the immediate post-
intervention time point with a significant score difference of 2.5 when comparing the intervention
and delayed groups. In addition, there was a significant score difference of 3.2 when comparing
baseline to 3-month follow-up for the two groups, suggesting a statistically significant intervention
effect to improve actual understanding of the basic elements of informed consent. The findings
demonstrated that one-time targeted education can improve actual informed consent understanding
one week after the intervention, but retention of these concepts may require periodic monitoring to
ensure comprehension throughout the course of a clinical trial.
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INTRODUCTION
In clinical trials of therapeutic medications and procedures, major codes of ethical research
practice state that it is mandatory for human subjects, or their representatives, to provide
written informed consent (Beachamp & Childress, 1994; Carlson, Boyd, & Webb, 2004;
Council for International Organization of Medical Sciences [CIOMS], 1993; Levine 1988;
National Institutes of Health [NIH], 1979). According to U.S. federal regulations, a valid
informed consent document requires eight basic elements about the research to be disclosed
to human subjects: (1) Explanation of the research and subjects’ expected participation; (2)
description of foreseeable risks to subjects; (3) description of benefits to subjects; (4)
disclosure of alternative courses of treatment; (5) description of how subjects’
confidentiality will be protected; (6) for research involving more than minimal risk, an
explanation of any compensation with respect to injury; (7) explanation of whom to contact
about the research and research subjects' rights; and (8) a statement that participation is
voluntary (U.S. Department of Health and Human Services [DHHS], 2009). Ethics
committees or Institutional Review Boards (IRBs) are required to review and approve the
process of obtaining informed consent and ensure that the eight basic elements are disclosed
in any given consent form (DHHS, 2009; Jefford & Moore, 2008). What is less enforced,
however, is the extent to which human subjects actually understand the informed consent
elements even after signing the consent form (Flory & Emanuel, 2004).
A 2004 literature review examined studies that assessed clinical trial subjects’ understanding
of the informed consent form through interventions that aimed to improve their perceived
and/or actual understanding (Flory & Emanuel, 2004). The review suggested “limited
evidence” that in-person, extended discussion interactions as part of the consent process
were more effective in improving informed consent understanding, compared to enhanced
consent form strategies (e.g., language simplifying or shortening the consent form) or video/
multi-media interventions. Furthermore, while test/feedback interventions demonstrated
effectiveness in improving knowledge scores, the authors criticized them for focusing more
on rote memorization concerning details of a specific clinical trial, rather than trying to
improve subjects’ understanding of the eight basic elements of informed consent.
Since 2004, there have been several intervention studies to increase informed consent
understanding in clinical trials, but the majority has assessed specifics of a clinical trial
rather than on the eight basic elements of informed consent (Campbell, Goldman, Boccia, &
Skinner, 2004; Hutchison, Cowan, & Paul, 2007; Moseley, Wiggins, & O’Sullivan, 2006;
Olver, Whitford, Denson, Peterson, & Olver, 2009; Sarkar et al., 2010; Wray, Stryker,
Winer, Demetri, & Emmons, 2007). While we do not view HIV/AIDS clinical trials as
unique in their informed consent process, we do know that there currently are over 1000
HIV/AIDS clinical trial protocols, with numerous sites per protocol, actively, or soon to be
recruiting potential subjects both nationally and internationally (NIH, 2010). Aside from one
intervention study to test a video’s effectiveness in improving informed consent
understanding among HIV-uninfected Haitian clinical trial enrollees (Joseph et al., 2006), no
other studies, to our knowledge, have tested interventions to improve actual informed
consent understanding among HIV-infected AIDS clinical trial enrollees.
The purpose of this pilot study was to gather preliminary data to determine the effectiveness
of targeted, in-person education to improve informed consent understanding among newly
Sengupta et al. Page 2













enrolled HIV-infected subjects in a U.S. Adult AIDS Clinical Trial (AACTG) site. The
AACTG conducts clinical trials of therapeutic drugs and strategies to treat HIV and HIV-
related infections (see https://actgnetwork.org/mission for AACTG’s complete mission). As
Flory & Emanuel (2004) recommended, we designed a study to test our educational
intervention, and focused on increasing actual understanding of the eight basic elements of




The pilot study was a randomized controlled study design, with a delayed intervention
control group, and two follow-up time points (immediate post-intervention and at 3-months).
Figure 1 illustrates the study design and data collection time points. A delayed intervention
was appropriate to uphold clinical equipoise since current informed consent procedures
implemented by the AACTG vary by site. Furthermore, while sites may include an
assessment of understanding, their procedures may or may not address all eight basic
elements of informed consent. This study was approved by the University of North Carolina
at Chapel Hill (UNC-CH) Biomedical Institutional Review Board and the UNC-CH General
Clinical Research Center.
Sample and Recruitment
The target population was newly enrolled HIV-infected subjects in any one of the protocols
conducted at the UNC-CH AACTG site in 2007–2008. “Newly enrolled” meant that
subjects were recruited into our study within the first month (Week 0 to Week 4) of their
recruitment into an AACTG protocol (study durations of protocols were between 2–4 years).
It is important to note that UNC-CH AACTG site’s informed consent procedures did not
include their own assessment of understanding before enrolling subjects. Furthermore, our
pilot study was independent of this site’s informed consent procedures. Study coordinators
responsible for particular AACTG protocols were, however, used as liaisons to access newly
enrolled subjects for our study. For the subjects who were interested in participating in this
study, written informed consent was obtained, followed by the baseline questionnaire
assessing perceived and actual understanding of the eight basic elements of informed
consent. Each subject received a $10 gift card for completing the baseline assessment.
Randomization
Computerized random assignment was done by a biostatistician, and concealed, numbered
envelopes with the random assignment groups (intervention or delayed intervention) were
given to the research team. To determine subjects’ assignments, the envelopes were
consecutively opened for each subject who incorrectly answered 4 or more items on the 21-
item instrument measuring actual understanding at baseline. Neither the research team nor
the subjects could be blinded to assignment.
Actual and Perceived Understanding Assessment
The Quality of Informed Consent (QuIC) is a measure to assess both perceived (12 items)
and actual understanding (20 items) of the eight basic elements of informed consent (Joffe,
Cook, Cleary, Clark, & Weeks, 2001). This measure was originally developed to assess
perceived and actual informed consent understanding in therapeutic cancer clinical trials,
and reported a mean score of 78% (standard deviation of 9.4) on the actual understanding
items. The QuIC was adapted for this study, which involved modifying the original QuIC’s
items to focus on HIV/AIDS clinical trials, reviewing this new set of items with PIs and
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study coordinators at the local AACTG, and pretesting a penultimate version of the
instrument with the local AACTG’s Community Advisory Board. After further modification
or deletion of items, the final version for HIV/AIDS clinical trials was comprised of 10
items measuring perceived understanding, and 21 items measuring actual understanding.
Response options for the adapted version remained the same as in the original QuIC:
perceived understanding items ranged from 5 (“I understood this very well”), to 1 (“I didn’t
understand this at all”); and actual understanding items ranged from “Agree,” “Unsure,” or
“Disagree.” We re-coded actual understanding items by giving a 1 for correctly answered
items (responses could be “Agree” or “Disagree), and 0 for incorrectly answered items
(responses could be “Agree” or “Disagree,” and “Unsure”). We added the number of correct
responses to obtain the summary score, with 21 being the highest score to represent actual
understanding of the basic elements of informed consent. Table 1 presents the items asked
for perceived and actual understanding, and to which basic elements of informed consent
they underlie.
Both the perceived and actual understanding items were administered at baseline and
immediate post-intervention. In addition, the perceived and actual understanding items were
administered at a 3-month follow-up time point to determine retention of actual informed
consent understanding after both groups received the targeted educational intervention.
Baseline assessments were 15–20 minutes in length, and included socio-demographic
questions and questions asking about motivations to participate. Immediate post-intervention
and 3-month follow-up assessments were 10–15 minutes in length, and conducted over the
telephone.
Intervention
Both intervention and delayed intervention groups received 20 minutes of targeted education
to improve their actual understanding of the eight basic elements of informed consent. We
tried to model the targeted educational intervention after what the AACTG study
coordinators typically do when obtaining consent from potential study participants before
they enroll. This included subjects being provided a copy of the consent form, and being
able to ask any questions of the AACTG protocol in which they were participating. The
main difference, however, was that, since our intervention took place soon after a participant
enrolled in a given AACTG protocol, the consent form we provided to them served as a
guide from which we could review with subjects all incorrectly answered items from the
baseline assessment, thus making it targeted education. For example, if a subject incorrectly
disagreed with “If I am injured or become ill as a result of participation in this clinical trial,
costs of any medical care related to the injury will be billed to me and/or my insurance
company,” the intervention would involve showing the subject where in the AACTG
consent form that statement was written, and what the statement meant in practical terms.
Data Analysis
Descriptive statistics were analyzed using PASW, version 18.0, and testing of the
effectiveness of the intervention occurred in SAS, version 9.2. Demographic characteristics
and motivations to participate were compared to make sure groups were similar on
demographic and other relevant variables; any of these variables that were not equally
distributed would be treated as confounders in the statistically analysis. We also calculated
Pearson correlation coefficients to see how well subjects’ actual understanding correlated
with their perceived understanding on the eight basic elements of informed consent at
baseline.
Next, we were interested in testing the effectiveness of the targeted educational intervention
to improve actual understanding of basic elements of informed consent. A biostatistician,
Sengupta et al. Page 4













blinded to assignment, used a repeated measures ANOVA with appropriate follow-up
contrasts to compare the actual understanding summary scores for the intervention and
delayed intervention groups at baseline, immediate post-intervention, and at the 3-month
follow-up, using an alpha level of .05. Estimates of the score difference for each of the
contrasts were reported, along with their associated p-values and 95% confidence intervals.
RESULTS
A total of 24 subjects who were asked to participate agreed to be in the pilot study. Only
three of the 24 subjects were not eligible for random assignment since their scores ranged
from 19/21 to a perfect score (21/21) at their baseline assessment. The remaining 21 subjects
were randomly assigned to the intervention (n = 12) and delayed intervention (n = 9) groups.
Thus, we did not meet our sample size requirement of 15 per group to estimate a 2-point (or
10%) actual understanding difference between groups at the immediate post-intervention.
Gift card incentives were provided for each follow-up time point and for the educational
intervention in which subjects participated.
Baseline Comparisons
Table 2 presents the descriptive statistics that demonstrate how the intervention and delayed
intervention groups were similar. This provided us some indication that the random
assignment worked, and that there were no socio-demographic or motivations to participate
variables we needed to treat as confounders. P-values are not presented in Table 2 because
of the small sample sizes of the descriptive variables’ sub-categories. Furthermore, the
correlation between perceived and actual understanding scores was moderate to strongly
positive (.59) at p < .002 (not shown in Table 2).
Testing the Effectiveness of the Educational Intervention
Of the 21 subjects who were randomized to the intervention or delayed intervention, 1 (5%)
subject assigned to the delayed intervention group became too ill to complete the pilot study
after completing the baseline assessment. One other subject (5%) who was assigned to the
intervention group was lost to follow-up at the 3-month assessment. For this subject, we
used maximum likelihood estimation to impute a single value to replace this subject’s 3-
month actual understanding score (Yuan, accessed 2010). Thus the sample sizes for the
intervention and delayed intervention groups to test the intervention were n = 12 and n = 8,
respectively.
Actual understanding of the basic elements of informed consent was measured by 21
informed consent knowledge items at baseline, immediate post-intervention, and at a follow-
up three months after the baseline assessment. To test our hypothesis that actual
understanding scores will improve more in the intervention group versus the delayed
intervention group, we compared the mean scores at each time point for both groups. Table
3 presents the repeated measures ANOVA estimates of score difference and their 95%
confidence intervals (CIs) (null value = 0), indicating how large the mean score differences
were at baseline, immediate post-intervention, and at the 3-month follow-up.
The estimate of −0.75, 95%CI(−2.5, .95) at baseline indicated no significant differences in
actual understanding of informed consent principles when comparing the intervention and
delayed intervention groups. At the immediate post-intervention time point, however, the
estimate increased to 2.5, 95%CI (0.76, 4.2), indicating a significant intervention effect on
actual understanding of the basic elements of informed consent at the immediate post-
intervention time point. At the 3-month follow-up—a time point at which both groups had
received the intervention (see Figure 1)—the estimate decreased to −.51, 95%CI (−2.2, 1.2),
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indicating that the improvement in actual understanding waned to less than baseline levels
approximately five weeks after both groups received the intervention. When we examined
the time effect on these groups, the baseline to follow-up difference estimate was 3.2,
95%CI (1.2, 5.2), indicating an intervention effect and better overall retention (i.e., actual
understanding) of the basic elements of informed consent in the intervention group than in
the delayed group by three points.
To examine which of the 21 items demonstrated the greatest improvement in actual
understanding of the basic elements of informed consent as a result of the targeted
educational intervention, we compared the number of correct responses for each item at
baseline and immediate post-intervention for the intervention and delayed intervention
groups (data not shown). At baseline, 10 of 21 items (#s 3, 4, 6, 9, 11, 12, 16–18, 20 from
Table 1) were incorrectly answered by at least 25% of the participants in the intervention
group. These 10 items reflected the following basic elements of informed consent: purpose
and subjects expected participation (item #s 3, 4, 6, and 9); risks (item #s 11–12);
alternatives to participation (item #16); confidentiality of data (item #17); injuries associated
with greater than minimal risk research (item #18); and voluntariness of consent to research
(item #20). At the immediate post-intervention time point, more participants in the
intervention group correctly responded to all 10 of these items, but only #s 12 and 18
demonstrated statistically significant improvement with p-values < .05.
DISCUSSION
Since the 2004 literature review assessing clinical trial subjects’ understanding of informed
consent (Flory & Emanuel, 2004), little has been published to rigorously test interventions to
improve actual understanding of the eight basic elements of informed consent stated in the
U.S. federal regulations (DHHS, 2009). While the AACTG and other HIV clinical trial
networks do incorporate assessments of understanding in their informed consent procedures,
this pilot study is a first step in helping to improve actual informed consent understanding of
the eight basic elements of informed consent among AACTG enrollees. Several
contributions can be noted.
First, the study developed and evaluated an adapted version of the QuIC instrument (Joffe et
al., 2001) to assess the eight basic elements of informed consent, rather than developing an
original instrument that assesses rote memorization of specifics on any given AACTG
protocol. This not only facilitates cross-trial site comparisons within the AACTG, but also
can help AACTG researchers within a trial site identify aspects of the informed consent that
their enrollees are not understanding, and educate enrollees on those particular elements. For
example, our findings demonstrated that items measuring purpose and subjects expected
participation, risks, alternatives to participation, confidentiality of data, injuries associated
with greater than minimal risk research, and voluntariness of consent to research may not
have been discussed with, or were confusing to AACTG enrollees at the time of the baseline
assessment. With targeted education, the intervention group improved their understanding of
these elements of informed consent. Two of the items measured—The treatment being
researched in my clinical trial has been proven to be the best treatment, and Compared with
standard treatments, my clinical trial does not carry any additional risks or discomforts—
are related to the therapeutic misconception often associated in clinical trials where subjects
misunderstand the clinical trial as being therapeutic (Miller, 2008). Indeed, these two items
also were incorrectly answered in the original QuIC study (Joffe et al., 2001), demonstrating
that these items may be difficult to understand across clinical trials regardless of the disease.
Lastly, the pilot study used a randomized controlled study design to test a targeted,
educational intervention to improve actual understanding of the basic elements of informed
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consent. This contribution responds to Flory’s and Emanuel’s (2004) recommendations to
employ rigorous methods to test an intervention, and to focus on interventions that
emphasize in-person discussions since other informed consent interventions (e.g., focus on
simplifying or shortening the consent form, and/or video/multi-media interventions) did not
demonstrate effectiveness to improve informed consent understanding (actual or perceived).
This study demonstrated a statistically significant intervention effect, with a 3-point
difference for follow-up versus baseline of the intervention and control groups. The targeted
educational intervention also has the advantage of being brief, and along with administering
the adapted QuIC instrument, could be feasible to do as part of any informed consent
process undertaken by an AACTG trial site. This would be our recommendation to AACTG
sites that would be interested in implementing initial informed consent education and
assessment to their recruitment process, and/or periodic monitoring to ensure comprehension
throughout the course of a clinical trial.
This pilot study does have some limitations that should be noted. The primary limitations
have to do with sample size and recruitment. We did not meet our intended sample size goal,
mainly because our subjects represented only 3 of 5 AACTG protocols from which we were
allowed to recruit, and at the time of our study, these protocols’ recruitment efforts were
either winding down, or these protocols were recruiting 1–2 individuals per month. Second,
we also were concerned with the possibility of selection bias, given that we were dependent
on the AACTG site’s study coordinators letting us know which subjects we could ask to
participate in our study. We expect this is the reason why all of the subjects who we were
allowed to approach agreed to participate in our pilot study. To minimize selection bias, the
ideal recruitment scenario for our study would have been that we could ask all newly
enrolled AACTG subjects to participate in our study to assess both refusal and participation
rates, and to possibly collect demographics data for the refusals. Despite not being able to
meet our intended sample size, and problems with our recruitment process, we were able to
minimize selection bias with very low loss to follow-up, as well as demonstrate
effectiveness of the targeted educational intervention. A third limitation is that our pilot
study subjects represented one U.S. AACTG site, HIV-infected adults, and enrollees in
therapeutic HIV/AIDS trials, thus decreasing generalizability to pediatric AIDS clinical
trials, international AACTG sites and possibly other U.S. AACTG sites, and HIV prevention
trials that may include non HIV-infected individuals. One final limitation relates to whether
using forced-choice checklists, like our adapted QuIC instrument, really measures actual
understanding of informed consent, based on a 2006 published study that compared methods
of assessing actual understanding of informed consent in HIV vaccine trials (Lindegger et
al., 2006). Based on our findings, we do agree with the authors that forced-choice checklists
may overestimate actual understanding, and used alone, will not help study participants
understand the basic concepts of informed consent. While our targeted educational
intervention did not use open-ended narratives and vignettes, as the Lindegger et al. (2006)
study recommended, we do believe that targeted education does allow for open-ended
discussion of the basic elements of informed consent, and is a more feasible option for
AACTGs to incorporate into their informed consent process since it would not require
additional resources to collect and analyze the open-ended (qualitative) data.
In conclusion, the informed consent process in AIDS clinical trials has not always been
successful in communicating to new enrollees the eight basic elements of informed consent
stated in the U.S. federal regulations. Learning these elements could be useful to enrollees to
better understand the clinical trial itself and their expected participation. Monitoring consent
in such a manner would ensure not only a signed agreement between researchers and
subjects, but also uphold the underlying assumption that subjects understand the content of
the consent form throughout the course of an AIDS clinical trial.
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Diagram of Study Design and Data Collection Time Points
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Table 1
Adapted QuIC Items Corresponding to the Eight Basic Elements of Informed Consent
8 Basic Elements of
Informed Consent
10 Perceived Understanding Items 21 Actual Understanding Items
(1) Explanation of the
purposes, description of
the research, along with
subjects’ expected
participation
1. The fact that your
treatment involves
research
2. Amount of time you will
be in the clinical trial
1. When I signed the consent form for my current HIV/AIDS
treatment, I knew that I was agreeing to participate in a
clinical trial.
2. I have been informed how long my participation in this
clinical trial will last.
3. In my clinical trial, one of the researchers’ major purposes
is to compare the effects (good and bad) of two or more
different ways of treating patients with HIV/AIDS, in
order to see which one is better.
4. In my clinical trial, one of the researchers’ purposes is to
test the safety of a new drug or new combination of drugs.
5. In my clinical trial, one of the researchers’ purposes is to
find out what effects (good or bad) a new treatment has on
me.
6. The treatment being researched in my clinical trial has
been proven to be the best treatment.
7. After I agreed to participate in my clinical trial, my
treatment was chosen randomly (by chance) from two or
more possibilities.
8. In my clinical trial, I have a chance of getting a placebo in
combination with treatment. A placebo is a pill that does
not contain any medicine or drug.
9. In my clinical trial, both my provider and I know which
treatment I am receiving.
10. The consent form I signed tells me what will happen when
I participate in my clinical trial.
(2) description of any
reasonably foreseeable
risks or discomforts to
subjects




11. If the treatment to which I have been assigned in my
clinical trial gives me side effects, the provider can
change it to another treatment.
12. Compared with standard treatments, my clinical trial does
not carry any additional risks or discomforts.
13. I was given a list of possible side effects relating to the
drugs studied in my clinical trial.
(3) description of any
benefits to subjects
4. Any direct benefits to you




clinical trial may benefit
future patients
14. The main reason AIDS Clinical Trials are done is to
improve the treatment of future HIV-positive or AIDS
patients.
15. By participating in this clinical trial, I am helping the




procedures or courses of
treatment
6. The alternatives to
participation in the
clinical trial
16. My providers did not offer me any alternatives besides
treatment in this clinical trial.
(5) information related
to the confidentiality of
data
7. That your data from the
clinical trial is kept
confidential
17. Because I am participating in a clinical trial, it is possible
that the study sponsor, government agencies, or others
who are not directly involved in my care could review my
medical records.
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8 Basic Elements of
Informed Consent







8. Who will pay for
treatment if you are
injured or become ill
because of participation
in this clinical trial
18. If I am injured or become ill as a result of participation in
this clinical trial, costs of any medical care related to the
injury will be billed to me and/or my insurance company.
(7) explanation of whom




9. Whom you should
contact if you have
questions or concerns
about the clinical trial
19. The consent form I signed lists the name of the person (or
persons) whom I should contact if I have any questions or
concerns about the clinical trial.
(8) a statement that
participation is voluntary
10. The fact that participation
in the clinical trial is
voluntary
20. I will have to remain in the clinical trial even if I decide
someday that I want to withdraw.
21. If I had not wanted to participate in this clinical trial, I
could have declined to sign the consent form.
Note: Perceived understanding items are prefaced with an introductory statement asking, How well did you understand the following aspects of
your clinical trial? (Response range: 1–5); actual understanding items’ response options are, “Agree,” “Unsure,” or “Disagree.”
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Table 2
Sociodemographics and Motivations to Participate in Clinical Trials Comparing Intervention and Delayed
Intervention Groups
Variables Intervention (n = 12) Delayed Intervention (n = 9)
Age (in years) Mean 39 (8) Mean 36 (10)
ACTG Protocol #
      5202 9 (75%) 7 (78%)
      5229 2 (17%) 1 (11%)
      5244 1 (8%) 1 (11%)
Gender
      Male 10 (83%) 9 (100%)
      Female 2 (17%) --
Race
      White 5 (42%) 6 (68%)
      Black 4 (33%) 2 (22%)
      Asian 1 (8%) 1 (11%)
      Mixed Race 2 (17%) --
Hispanic 4 (33%) 1 (11%)
Marital Status
      Single 6 (50%) 7 (78%)
      Married 3 (25%) --
      Committed relationship/not married 2 (17%) 2 (22%)
      Widowed 1 (8%) --
Education
      11th grade and under 2 (17%) 1 (11%)
      High school/G.E.D 2 (17%) 2 (22%)
      Some college or training 5 (42%) 2 (22%)
      College degree 1 (8%) 1 (11%)
      Some graduate school or graduate degree 2 (17%) 3 (33%)
English Second Language 3 (25%) 2 (22%)
Health Insurance Status
      No insurance
      Private 5 (42%) 2 (22%)
      Medicare/disability 3 (25%) 7 (78%)
      Medicaid 1 (8%) --
      Insurance through 1 (8%) --
      the hospital 1 (1%) --
      AIDS Drug Assistance Program (ADAP) 1 (1%) --
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Variables Intervention (n = 12) Delayed Intervention (n = 9)
Past Participation in Clinical Trials 5 (42%) 2 (22%)
Who influences your decision to participate? (influences a little or very influential)
      Personal doctor
      Study Coordinator 9 (75%) 6 (67%)
      Husband/Wife 8 (67%) 8 (89%)
      Partner 3 (25%) --
      Friend 4 (33%) 3 (33%)
      Yourself 1 (8%) 2 (22%)
11 (92%) 7 (78%)
Helping others like yourself living with HIV 8 (67%) 9 (100%)
Free AIDS medication 8 (67%) 4 (44%)
Help scientists find a cure 12 (100%) 9 (100%)
Help you be healthy so you can take care of your family 9 (75%) 8 (89%)
Free medical care 7 (58%) 3 (33%)
Be able to live longer 10 (78%) 7 (78%)
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Table 3
Repeated Measures ANOVA with Contrasts
Baseline Immediate Post 3-Month
Follow-Up
Intervention, n = 12 15.3 20.0 17.4 3-Month Follow-Up
Vs. Baseline Effect
Delayed Intervention, n = 8 16.0 17.1 17.9
Estimate (95% CI), p-value −0.75 (−2.45, 0.95), .38 2.46 (0.76, 4.16), .006 −0.51 (−2.21, 1.19), .55 3.21 (1.23, 5.18), .002
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